Maternal serum Lamin A is a potential biomarker that can predict adverse pregnancy outcomes.

ABSTRACT:

Background

Maternal serum Lamin A (LMNA) was reported to have potential diagnostic value in the prenatal diagnosis of congenital heart disease (CHD). In this study, we aimed to further assess the prognostic value of maternal serum LMNA in predicting adverse pregnancy outcomes.

Methods

A prospective screening study was performed on singleton pregnancies at 15-18 weeks of gestation. After a routine test for alpha fetoprotein (AFP), chorionic gonadotropin (hCG), and unconjugated estriol (uE3), serum LMNA levels were measured. Serum LMNA levels were then converted into multiples of the median (MoM). The median MoM values for adverse pregnancy outcomes were compared with those in normal pregnancies. For diseases with differential LMNA expression in the prospective study, another

SUBMITTER: Chen L 

PROVIDER: S-EPMC8924630 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature